RhumbLine Advisers
SCTX

RhumbLine Advisers’s Scribe Therapeutics Inc SCTX Stock Holding History

RhumbLine Advisers’s Portfolio SCTX Stock Details SCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$164K Buy
+8,897
New +$235K ﹤0.01% 3356

Other funds holding SCTX

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Menlo Ventures Management
Menlo Ventures Management Menlo Park, California $241M AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $96.6B AUM 22.52% 1-Year Est. Return

RhumbLine Advisers's SCTX Position: Q3 2026 in Review

RhumbLine Advisers opened a new position in Scribe Therapeutics Inc (SCTX) in Q3 2026: 8,897 shares worth $164K. The stake represents ﹤0.01% of the portfolio and ranks #3356 among its holdings.

23 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.

  • RhumbLine Advisers held 8,897 shares of Scribe Therapeutics Inc worth $164K as of Q3 2026.
  • Scribe Therapeutics Inc was a new RhumbLine Advisers position in Q3 2026.
  • Scribe Therapeutics Inc made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3356 holding.
  • 23 funds tracked by Wall St. Rank held Scribe Therapeutics Inc as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.